Barry J. Cusack
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barry J. Cusack has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Hervé Gambliel
VA Medical Center, 500 West Fort Street, Boise, ID 82702-4598, USA
2 shared publicationsRichard D. Olson
VA Medical Center, 500 West Fort Street, Boise, ID 82702-4598, USA
2 shared publicationsB. Musser
Research Service, VA Medical Center (111), Boise, USA
1 shared publicationBeth Musser
VA Medical Center, 500 West Fort Street, Boise, ID 82702-4598, USA
1 shared publicationH. Charlier
Mountain States Tumor and Medical Research Institute, Boise, USA
1 shared publicationH. Gambliel
Research Service, VA Medical Center (111), Boise, USA
1 shared publication
Latest Publications
- 23 March 2006
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 58 (4) , 517-526
Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism
- 23 March 2006
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 58 (4) , 517-526
Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism
- 1 December 2004
- Published by Elsevier in The American Journal of Geriatric Pharmacotherapy
- Vol. 2 (4) , 274-302
Pharmacokinetics in older persons
- 1 December 2004
- Published by Elsevier in The American Journal of Geriatric Pharmacotherapy
- Vol. 2 (4) , 274-302
Pharmacokinetics in older persons
- 1 February 2003
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 51 (2) , 139-146
Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats
Purpose. Although dexrazoxane (ICRF-187) is used clinically to protect against doxorubicin cardiotoxicity, the age-related effect of dexrazoxane on doxorubicin pharmacokinetics has not been well studied. Methods. We therefore examined the effect of pretreatment with dexrazoxane (50 mg kg–1 i.p. 1 h prior to administration of doxorubicin 2 mg kg–1 i.v. bolus) on doxorubicin and doxorubicinol pharmacokinetics in Fischer 344 rats at 5 months of age (young adult) and 22 months of age (old). Results. Dexrazoxane had no major effects on doxorubicin or doxorubicinol pharmacokinetics in plasma or heart in either young or old rats. However, age had significant effects on anthracycline pharmacokinetics. Early plasma concentrations were increased and systemic clearance of doxorubicin was decreased in old compared with young rats. Cardiac concentrations of doxorubicin (AUC) were significantly increased in old rats. In addition cardiac doxorubicinol concentrations (AUC 0–72 h) were increased by over 80% in old compared to young rats. Conclusion. The results suggest that dexrazoxane does not alter doxorubicin pharmacokinetics. In contrast, aging in the rat model is associated with altered doxorubicin and doxorubicinol pharmacokinetics, in particular in the heart. These changes could increase the risk of anthracycline cardiotoxicity with age.
- 1 February 2003
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 51 (2) , 139-146
Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats
Purpose. Although dexrazoxane (ICRF-187) is used clinically to protect against doxorubicin cardiotoxicity, the age-related effect of dexrazoxane on doxorubicin pharmacokinetics has not been well studied. Methods. We therefore examined the effect of pretreatment with dexrazoxane (50 mg kg–1 i.p. 1 h prior to administration of doxorubicin 2 mg kg–1 i.v. bolus) on doxorubicin and doxorubicinol pharmacokinetics in Fischer 344 rats at 5 months of age (young adult) and 22 months of age (old). Results. Dexrazoxane had no major effects on doxorubicin or doxorubicinol pharmacokinetics in plasma or heart in either young or old rats. However, age had significant effects on anthracycline pharmacokinetics. Early plasma concentrations were increased and systemic clearance of doxorubicin was decreased in old compared with young rats. Cardiac concentrations of doxorubicin (AUC) were significantly increased in old rats. In addition cardiac doxorubicinol concentrations (AUC 0–72 h) were increased by over 80% in old compared to young rats. Conclusion. The results suggest that dexrazoxane does not alter doxorubicin pharmacokinetics. In contrast, aging in the rat model is associated with altered doxorubicin and doxorubicinol pharmacokinetics, in particular in the heart. These changes could increase the risk of anthracycline cardiotoxicity with age.
- 1 January 2002
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 2 (2) , 099-110
Effect of Aging on Cardiac Contractility in a Rat Model of Chronic Daunorubicin Cardiotoxicity
Because the risk of chronic anthracycline cardiotoxicity increases with age, the effect of chronic daunorubicin was compared in young (6–9 mo) and senescent (24–26 mo) Fischer 344 rats in cumulative doses of 12 or 18 mg/kg. Senescent rats treated using 18 mg/kg of daunorubicin did not survive because of daunorubicin toxicity. Rats were euthanized 1 wk after the last dose of daunorubicin and ex vivo studies of isometric cardiac contractile function were done in left ventricular trabeculae carneae. In senescent rats given 12 mg/kg of daunorubicin, it caused significant impairment of contractility (dS/dt at 15 cpm; p=0.001) that was not observed in either young adult group. In addition, the effect of 12 mg/kg of daunorubicin on contractility in senescent rats was significantly reduced compared to that in young rats administered 12 mg/kg of daunorubicin (p2+-induced contractility. Daunorubicinol, but not daunorubicin, concentrations were increased in the senescent rat heart tissue. This suggests that chronic daunorubicin cardiotoxicity increases with age, at least partly resulting from sarcoplasmic reticulum dysfunction caused by increased anthracycline exposure.
- 1 January 2002
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 2 (2) , 099-110
Effect of Aging on Cardiac Contractility in a Rat Model of Chronic Daunorubicin Cardiotoxicity
Because the risk of chronic anthracycline cardiotoxicity increases with age, the effect of chronic daunorubicin was compared in young (6–9 mo) and senescent (24–26 mo) Fischer 344 rats in cumulative doses of 12 or 18 mg/kg. Senescent rats treated using 18 mg/kg of daunorubicin did not survive because of daunorubicin toxicity. Rats were euthanized 1 wk after the last dose of daunorubicin and ex vivo studies of isometric cardiac contractile function were done in left ventricular trabeculae carneae. In senescent rats given 12 mg/kg of daunorubicin, it caused significant impairment of contractility (dS/dt at 15 cpm; p=0.001) that was not observed in either young adult group. In addition, the effect of 12 mg/kg of daunorubicin on contractility in senescent rats was significantly reduced compared to that in young rats administered 12 mg/kg of daunorubicin (p2+-induced contractility. Daunorubicinol, but not daunorubicin, concentrations were increased in the senescent rat heart tissue. This suggests that chronic daunorubicin cardiotoxicity increases with age, at least partly resulting from sarcoplasmic reticulum dysfunction caused by increased anthracycline exposure.